A large number of these products are developed by small or mid-sized start-ups indicating that they are slowly becoming the centres of innovative translational research in India. Government grants alongwith scientists having domain specific expertise has helped a majority of them break the barrier associated with size of the company.

The Indian companies have the potential to become true global players in biologicals and biosimilars mirroring the strong position it has in small molecule generics. For this to come to fruition India needs a concerted approach to boost both research and development in biopharma and strengthen the wider ecosystem supporting this segment of the industry.